ONC201, also called TIC10, is a small molecule inhibitor that is water soluble, orally bioavailable, and can cross the blood brain barrier. It functions as an Akt/ERK inhibitor and can assist in inhibiting apoptosis mediated by TRAIL. This makes it an intriguing factor for the treatment of pancreatic adenocarcinoma. Studies have also shown that ONC201 has a synergistic effect in vivo with ABT263, a Bcl-2 inhibitor in various types of cancers (2). Further research of pancreatic adenocarcinoma treatments show a beneficial synergistic interaction between ONC201 and gemcitabine, another chemotherapy (1). The researchers would like to expand on synergy between ONC201 and additional therapies to target pancreatic adenocarcinoma. The use of gemcitabine is not ideal as it is not specifically targeted to the cancer, and therefore may cause many adverse clinical side effects.
1. https://www.sciencedirect.com/science/article/pii/S0006291X16308142
Recent comments